GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GlaxoSmithKline Consumer Nigeria's cash to debt ratio for the quarter that ended in Jun. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GlaxoSmithKline Consumer Nigeria could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for GlaxoSmithKline Consumer Nigeria's Cash-to-Debt or its related term are showing as below:

NSA:GLAXOSMITH' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.06 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, GlaxoSmithKline Consumer Nigeria's highest Cash to Debt Ratio was No Debt. The lowest was 10.06. And the median was No Debt.

NSA:GLAXOSMITH's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.93 vs NSA:GLAXOSMITH: No Debt

GlaxoSmithKline Consumer Nigeria Cash-to-Debt Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Cash-to-Debt Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

10.06

94.78

7,271.40

No Debt

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Cash-to-Debt

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Consumer Nigeria's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Cash-to-Debt falls into.

GlaxoSmithKline Consumer Nigeria Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GlaxoSmithKline Consumer Nigeria's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

GlaxoSmithKline Consumer Nigeria had no debt ⁽¹⁾.

GlaxoSmithKline Consumer Nigeria's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

GlaxoSmithKline Consumer Nigeria had no debt ⁽¹⁾.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GlaxoSmithKline Consumer Nigeria Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Cash-to-Debt : No Debt (1) (As of Jun. 2023)